MGMT and glioblastoma: However, with regard to the impact of lomustine in recurrent glioblastoma therapy as well as recent evidence for TMZ-lomustine combination to significantly improve survival in patients with newly diagnosed MGMT promoter methylated glioblastoma [9,11,16], there arises the question for the potential of a gap junction targeted therapeutic approach in the context of lomustine application.